Expertise in
7
conditions

Sarah J. Tabrizi

UCL Queen Square Institute Of Neurology, 
London, ENG, GB 
Expertise in
7
conditions
UCL Queen Square Institute Of Neurology, 
London, ENG, GB 

Overview

Sarah Tabrizi practices practicing medicine in London, United Kingdom.

Ms. Tabrizi is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Huntington Disease, Movement Disorders, Dementia, Chorea, and Gastrostomy.

She is actively involved in clinical research, co-authoring 273 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

UCL Queen Square Institute Of Neurology, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease
A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

270 Total Publications

Targeting toxic HTT1a could be the key to treating Huntington disease.
Targeting toxic HTT1a could be the key to treating Huntington disease.
Journal: Nature reviews. Neurology
Published: May 26, 2026

Frequently Asked Questions about Sarah J. Tabrizi

Is Sarah J. Tabrizi a top-rated expert for Huntington Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Sarah J. Tabrizi is classified as an Elite expert for Huntington Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sarah J. Tabrizi participate in research or clinical trials?

Yes. Sarah J. Tabrizi has published 270 articles and abstracts on conditions like Huntington Disease. You can view a list of Sarah J. Tabrizi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tabrizi's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile